# Accuri Cytometers

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accuri-cytometers

- Industry: Biotechnology
- Headquarters: Ann Arbor, US
- Website: www.accuricytometers.com
- Total disclosed funding: $28M
- Latest round: Series E (Jul 12, 2010)
- Investors on record: 6

## About

Accuri Cytometers, Inc. develops innovative flow cytometry solutions to enhance cell analysis capabilities for research and clinical applications, contributing to advancements in cellular biology and medicine.Accuri Cytometers, Inc., founded in 2004 in Ann Arbor, US, specializes in flow cytometry technology. The company underwent a significant transition when it was acquired by Becton, Dickinson and Company following Baird Venture Partners' exit in February 2011. The total amount raised by the company across its funding rounds is USD 6.00 mn, with the latest funding round being Series E. This funding was backed by investors including Arboretum Ventures, Baird Capital Partners, Credit Suisse, F-Prime Capital, and Flagship Pioneering.Accuri Cytometers, Inc. offers a range of flow cytometry instruments and reagents designed for precise cell analysis in both research and clinical environments. Their key products include the BD FACSDiscover™ A8 Cell Analyzer and the BD Rhapsody™ single-cell analysis systems, which facilitate detailed gene expression studies. Additionally, the company provides an array of flow cytometry reagents and the BD Horizon™ series of innovative fluorochromes, targeting a diverse clientele, including academic institutions and pharmaceutical firms across North America, Europe, and Asia-Pacific regions.Accuri Cytometers generates revenue primarily through direct sales of its sophisticated instruments and reagents, complemented by service contracts. The B2B transaction model often involves bulk orders from clients requiring laboratory analysis equipment. The firm's flagship products play a crucial role in revenue generation, typically offered with bundled service options to enhance efficiency. Subscription models for software solutions are also available, ensuring continuous updates and support for clients.Accuri Cytometers plans to innovate with upcoming products focused on enhancing flow cytometry capabilities, with specific release dates yet to be announced. The company is looking to expand its market presence in Asia-Pacific and Europe, targeting completion of this expansion strategy by 2015. The recent funding of USD 6.00 mn raised in the Series E round will be allocated to support new product development and market penetration efforts, following the strategic shift post-acquisition by Becton, Dickinson and Company.

## Funding rounds

- Series E, Jul 12, 2010, $6M — Flagship Pioneering, Baird Capital Partners, Arboretum Ventures, Credit Suisse, F-Prime Capital
- Series D, Jul 13, 2009, $4M — Flagship Pioneering, Baird Capital Partners, Arboretum Ventures, Credit Suisse, F-Prime Capital
- Series C, Jul 8, 2008, $13M — Flagship Pioneering, Baird Capital Partners, Western Technology Investment, Arboretum Ventures, F-Prime Capital
- Series B, Apr 16, 2007, $5M — Baird Capital Partners, Arboretum Ventures

## Investors

- Baird Capital Partners (https://capitalatlas.ai/funds/baird-capital-partners) — Series B, Series C, Series D, Series E
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series B, Series C, Series D, Series E
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series C, Series D, Series E
- Western Technology Investment (https://capitalatlas.ai/funds/western-technology-investment) — Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series C, Series D, Series E
- Credit Suisse (https://capitalatlas.ai/funds/credit-suisse) — Series D, Series E